Comments made by HeartWare CEO Doug Godshall seem to be in conflict with those of principal ENDURANCE trial investigator Dr. Joseph Rogers, putting analysts on edge. Shares of HeartWare International (NSDQ:HTWR) are on watch in the wake of negative commentary from a Northland Capital Markets analyst. Analyst Suraj Kalia cited “glaring inconsistencies” between statements made by a principal investigator for HeartWare International’s pivotal ENDURANCE trial for the company’s ventricular-assist device (VAD) as destination therapy and recent remarks made by the HeartWare CEO Doug Godshall on calls with financial analysts.
Help employers find you! Check out all the jobs and post your resume.
